Determining PARP Inhibition as a Treatment Strategy in Melanoma Based on Homologous Recombination Deficiency-Related Loss of Heterozygosity.

Zhou, Alice; Butt, Omar; Ansstas, Michael; Mauer, Elizabeth; Khaddour, Karam; Ansstas, George

Zhou, Alice; Butt, Omar; Ansstas, Michael; Mauer, Elizabeth; Khaddour, Karam; Ansstas, George.

Afiliação

Zhou A; Division of Medical Oncology, Department of Internal Medicine, Washington University in St. Louis, St. Louis, Missouri.
Butt O; Division of Medical Oncology, Department of Internal Medicine, Washington University in St. Louis, St. Louis, Missouri.
Ansstas M; Division of Medical Oncology, Department of Internal Medicine, Washington University in St. Louis, St. Louis, Missouri.
Mauer E; Tempus Laboratories Inc., Chicago, Illinois.
Khaddour K; Division of Hematology and Oncology, University of Illinois Chicago, Chicago, Illinois.
Ansstas G; Division of Medical Oncology, Department of Internal Medicine, Washington University in St. Louis, St. Louis, Missouri.

J Natl Compr Canc Netw ; 21(7): 688-693.e3, 2023 07.

Article em En | MEDLINE | ID: mdl-37433433

Assuntos

Melanoma; Inibidores de Poli(ADP-Ribose) Polimerases; Humanos; Inibidores de Poli(ADP-Ribose) Polimerases/farmacologia; Inibidores de Poli(ADP-Ribose) Polimerases/uso terapêutico; Melanoma/tratamento farmacológico; Melanoma/genética; Imunoterapia; Perda de Heterozigosidade; Recombinação Homóloga

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Temas: Geral / Tipos_de_cancer / Pele Base de dados: MEDLINE Assunto principal: Inibidores de Poli(ADP-Ribose) Polimerases / Melanoma Limite: Humans Idioma: En Revista: J Natl Compr Canc Netw Assunto da revista: NEOPLASIAS Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google